Advances In™ Diabetes: Considerations for the Adolescent Patient Population in Type 2 Diabetes

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

The prevalence of type 2 diabetes mellitus (T2DM) in adolescents and young adults is on the rise. There are multiple indicators establishing that diabetes is and will continue to be a major healthcare issue in terms of economic, societal, and personal impact. Evidence also suggests that young-onset T2DM has a more aggressive disease phenotype, leading to premature development of complications, with adverse effects on quality of life and unfavorable effects on long-term outcomes, raising the possibility of a future public health catastrophe. Type 2 diabetes in children and adolescents presents several challenges for clinicians and patients, differing from their adult counterparts. Current therapies indicated for use in children and adolescents with T2DM are limited to metformin and insulin. Few studies have examined other antihyperglycemic agents in children and adolescents, and although there are many ongoing studies, they face several challenges from both a trial design and a regulatory standpoint. As a result, the current therapeutic options for children and adolescents with T2DM is comparatively limited compared with adult patients, and long-term glycemic control can be more challenging to maintain.

Benefits of Participating

• Learn about strategic measures to improve on care of pediatric patients with T2DM, not limited to treatment options, including ways to address compliance and adherence, and methods to increase patient education
• Increase awareness of current guidelines and recommendations for treatment of T2DM in children and adolescents
• Gain knowledge about best practices as a way to enhance clinical decision-making when examining treatment options available for the pediatric population with T2DM

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novo Nordisk Inc.

Target Audience

This educational activity is directed toward primary care physicians, pediatricians, endocrinologists, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of pediatric T2DM.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Identify unique challenges in pediatric patients with T2DM, including treatment options, compliance, and barriers for new clinical trials in antihyperglycemic agents
• Review current guidelines and recommendations for treatment of pediatric patients with T2DM
• Evaluate ongoing clinical trials of antihyperglycemic agents in the treatment of pediatric patients with T2DM

Faculty, Staff, and Planners’ Disclosures

Faculty

Kristen Nadeau, MD, MS
Professor of Pediatrics
Research Director, Pediatric Endocrinology
Research Director, Pediatric Bariatric Surgery
Co-Chair, CCTSI Scientific Advisory Committee (SARC)
Director, Mentored Scholarly Activity (MSA), University of Colorado SOM
University of Colorado Medicine
Denver, CO

Disclosures: Dr. Kristen Nadeau has no relevant financial relationships with commercial interests to disclose.

Dr. Amy Sanghavi Shah, MD, MS
Associate Professor
Division of Endocrinology
Director, Adolescent Type 2 Diabetes Program
Cincinnati Children’s Hospital Medical Center
Cincinnati OH

Disclosures: Grant/Research Support: National Institutes of Health; Speakers Bureau: Akcea Pharmaceuticals

The staff of Physicians' Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER^® or the companies that provided commercial support for this program.